Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028 - Visiongain Report

LONDON, June 12, 2018 /PRNewswire/ --

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis

The global inflammatory bowel diseases (IBD) drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023. Biologic therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 196-page report you will receive 141 charts- all unavailable elsewhere.

The 196-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2018-2028

• Submarket forecasts from 2018-2028:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators

• Revenue forecast from 2018-2028 for 17 leading products:
• Humira
• Remicade
• Lialda
• Asacol
• Pentasa
• Xifaxan
• Cimzia
• Tysabri
• Simponi
• Canasa/Salofalk
• Entyvio
• Apriso
• Medrol
• Neoral
• Entocort
• Uceris
• Azulfidine

• Revenue forecasts from 2018-2028 for 11 countries:
• US
• Japan
• Germany, France, UK, Spain and Italy (EU5)
• Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.

Visiongain's study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis.

To request a report overview of this report, please contact Sara Peerun at [email protected] or refer to our website : https://www.visiongain.com/Report/2208/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2018-2028

Companies Listed 

4SC
Abbott Laboratories
AbbVie
Ablynx
Actavis
Active Biotech
Ajinomoto
Alfasigma Group
Allergan
Almirall
Amgen
Aptalis Pharmaceuticals
Astellas
AstraZeneca
Athersys
Atlantic Healthcare
Avaxia Biologics
BioLineRx
Biosafe
Boehringer Ingelheim
Calico
Celgene
Celltrion
Centocor Ortho Biotech
Cipla
Coherus Biosciences
Coronado Biosciences
Cosmo Pharmaceuticals
Dr. Falk Pharma
Eddingpharm
Elan Pharmaceuticals
Epirus Biopharmaceuticals
Ferring
Forest Laboratories
Galapagos
Giaconda
Google
Harbor Biosciences
Hospira
Immunic
InDex Pharmaceuticals
Infinity Pharmaceuticals
Isis Pharmaceuticals
Janssen Biotech
Johnson & Johnson
Kissei Pharmaceutical Co., Ltd
LG Sciences
Lupin
MedImmune
Mochida
Mutare Health
Mylan Pharmaceuticals
Neovacs
Nisshin Kyorin
Nogra Pharma
NovaMedica
Novartis
Oncobiologics
Ortho Biotech
Osiris Therapeutics
Otsuka
Ovamed
Palau Pharma
Par Pharmaceuticals
Pendopharm
Perrigo
Pfenex
Pfizer
Pharmascience
Pluristem Therapeutics
Qu Biologics
Quest Diagnostics
Ranbaxy Laboratories
Receptos
RedHill Biopharma
Reliance Life Sciences
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus
Sequella
Shire Pharmaceuticals
Sigmoid Pharma
Soligenix
SonarMD
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
TiGenix
Toray Industries
Torrent Pharmaceuticals Ltd.
TxCell
UCB
Valeant
Warner Chilcott
Zeria Pharmaceutical
Zydus Cadila

To see a report overview, please e-mail Sara Peerun on [email protected]

SOURCE Visiongain